Synlogic announces publication of Synpheny-1 Phase 2 study results

Synlogic announced the publication of results from its Synpheny-1 Phase 2 study of its drug candidates, labafenogene marselecobac and SYNB1618 in patients with phenylketonuria in the journal Nature Metabolism. The publication, entitled “Efficacy and Safety of a Synthetic Biotic for Treatment of Phenylketonuria: a Phase 2 Clinical Trial” is now available online at https://www.nature.com/articles/s42255-023-00897-6. The paper includes a comprehensive review of the data, showing clinically meaningful, dose-dependent reductions in plasma phenylalanine. “These positive results build on a body of data supporting the role of labafenogene marselecobac for patients with PKU,” said Dr. Neal Sondheimer, Head of Clinical Development at Synlogic. “These findings re-enforce our urgency to complete Synpheny-3, the pivotal trial now underway, and advance this potential new treatment to the many patients who need it. The study was completed with the participation of clinical teams at University of Pittsburgh, Mount Sinai Hospital, Washington University, Oregon Health & Science University, University of Texas-Houston, Vanderbilt University, University of Colorado and University of Florida.